Mack Randall 4
4 · Recro Pharma, Inc. · Filed Oct 2, 2017
Insider Transaction Report
Form 4
Mack Randall
Senior VP, Development
Transactions
- Tax Payment
Common Stock
2017-09-28$9.04/sh−4,649$42,027→ 20,113 total - Exercise/Conversion
Common Stock
2017-09-28+15,000→ 24,762 total
Footnotes (1)
- [F1]On September 28, 2017, the Compensation Committee of the Board of Directors of the Issuer determined that performance-vesting criteria were met with regard to 15,000 performance-based restricted stock units, which were converted into 15,000 shares of common stock on a one-for-one basis.